Here is a data-driven look at Natco Pharma Limited (NATCOPHARM), covering financial performance, valuation, and shareholding trends.
Natco Pharma Revenue Trend
Natco Pharma Limited reported revenue of ₹4,784 Cr in FY2025, a 15.9% increase from ₹4,127 Cr in FY2024.
Natco Pharma Limited has delivered a 19.2% revenue CAGR over 10 years — strong, sustained top-line expansion from ₹825 Cr to ₹4,784 Cr.
Natco Pharma Limited's ₹4,784 Cr revenue base puts it in the mid-sized bracket among pharmaceuticals companies in India.
Natco Pharma Limited has posted revenue growth for 3 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹4,784 Cr | +15.9% |
| FY2024 | ₹4,127 Cr | +46.8% |
| FY2023 | ₹2,812 Cr | +37.6% |
| FY2022 | ₹2,044 Cr | -5.2% |
| FY2021 | ₹2,156 Cr | — |
View Natco Pharma Limited's full 10-year revenue trend with CAGR analysis →
Natco Pharma Profitability
Natco Pharma Limited turned in a net profit of ₹1,883 Cr for FY2025. That's 35.7% better than the ₹1,388 Cr earned in FY2024.
The company squeezed out better margins in FY2025, with net margin at 39.4% versus 33.6% in FY2024.
Per-share earnings moved to ₹105.26 in FY2025 from ₹77.34 in FY2024.
Is Natco Pharma Undervalued
Natco Pharma Limited shares are currently trading at ₹929.10.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Natco Pharma Shareholding Pattern
Promoters haven't moved — their 49.4% holding has been unchanged for 4 quarters.
Foreign investors held 17.0% of the company as of June 2026, up year-over-year from 14.1%.
DII ownership is at 5.6%, down from the 5.9% recorded a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 49.4% | 17.0% | 5.6% | 28.0% |
| Mar 2026 | 49.4% | 17.4% | 5.5% | 27.8% |
| Dec 2025 | 49.5% | 15.2% | 5.4% | 30.0% |
| Sep 2025 | 49.5% | 14.1% | 5.9% | 30.6% |
Track quarterly shareholding changes for Natco Pharma Limited →
Natco Pharma Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹86.31B (up 25.0% YoY from ₹69.06B).
Top categories: Other Assets (35.9%), Property, Plant & Equipment (30.8%), Receivables (14.4%).
Of the ₹86.31B in liabilities and equity, 88.2% is shareholder equity, 3.2% is interest-bearing debt, and 8.6% is operating liabilities. Over the year, debt is down 24.7% and equity is up 30.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 4.41B |
| Receivables | 12.47B |
| Inventories | 7.66B |
| Property, Plant & Equipment | 26.57B |
| Investments | 1.53B |
| Intangibles & Goodwill | 2.66B |
| Other Assets | 31.01B |
| Category | Value |
|---|---|
| Equity | 76.12B |
| Short-term Debt | 2.75B |
| Long-term Debt | 46.00M |
| Trade Payables | 2.75B |
| Other Liabilities | 4.64B |
Natco Pharma Key Takeaways
In summary, Natco Pharma Limited (NATCOPHARM) presents the following picture for fundamental analysts.
Revenue of ₹4,784 Cr in FY2025, up 15.9% year-over-year.
Long-term revenue has been compounding at 19.2% annually over 10 years.
The company is profitable, with a net margin of 39.4% and net income of ₹1,883 Cr.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Natco Pharma Limited.